Advertisement

Primary systemic amyloidosis. Comparison of melphalan/prednisone versus colchicine

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      This is the first prospectively randomized study of the use of melphalan/prednisone and colchicine in the treatment of primary systemic amyloidosis. One hundred one patients were stratified according to their dominant clinical manifestation. Forty-nine patients initially received melphalan/prednisone and eight subsequently had colchicine added to their regimen. Fifty-two patients initially received colchicine and 35 subsequently required melphalan/prednisone because of progressive disease. There was no difference in survival when the two groups were analyzed in aggregate (melphalan/prednisone, 25.2 months versus colchicine, 18 months; p = 0.23). When the survival of patients receiving only one regimen was analyzed or when survival was analyzed from the time of entry into the study to the time of death or progression of disease, significant differences (p <0.001 and p <0.0001, respectively) were evident, favoring melphalan/prednisone. This study suggests that melphalan/prednisone is superior to colchicine in the treatment of primary amyloidosis, but to confirm this impression, a study without a crossover group is necessary.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kyle RA
        • Bayrd ED
        Amyloidosis: review of 236 cases.
        Medicine (Baltimore). 1975; 54: 271-299
        • Kyle RA
        • Greipp PR
        Amyloidosis (AL): clinical and laboratory features in 229 cases.
        Mayo Clin Proc. 1983; 58: 665-683
        • Osserman EF
        • Takatsuki K
        • Talal N
        Multiple myeloma I. The pathogenesis of “amyloidosis”.
        Semin Hematol. 1964; 1: 3-85
        • Glenner GG
        • Terry W
        • Harada M
        • Isersky C
        • Page D
        Amyloid fibril proteins: proof of homology with immunoglobulin light chains by sequence analyses.
        Science. 1971; 172: 1150-1151
        • Terry WD
        • Page DL
        • Kimura S
        • Isobe T
        • Osserman EF
        • Glenner GG
        Structural identity of Bence Jones and amyloid fibril proteins in a patient with plasma cell dyscrasia and amyloidosis.
        J Clin Invest. 1973; 52: 1276-1281
        • Cohen AS
        • Wegelius O
        Classification of amyloid: 1979–1980.
        Arthritis Rheum. 1980; 23: 644-645
        • Kyle RA
        • Bayrd ED
        “Primary” systemic amyloidosis and myeloma: discussion of relationship and review of 81 cases.
        Arch Intern Med. 1961; 107: 344-353
        • Costa G
        • Engle Jr, RL
        • Schilling A
        • et al.
        Melphalan and prednisone: an effective combination for the treatment of multiple myeloma.
        Am J Med. 1973; 54: 589-599
        • Cohen HJ
        • Lessin LS
        • Hallal J
        • Burkholder P
        Resolution of primary amyloidosis during chemotherapy: studies in a patient with nephrotic syndrome.
        Ann Intern Med. 1975; 82: 466-473
        • Jones NF
        • Hilton PJ
        • Tighe JR
        • Hobbs JR
        Treatment of “primary” renal amyloidosis with melphalan.
        Lancet. 1972; II: 616-619
        • Horne III, MK
        Improvement in amyloidosis (letter).
        Ann Intern Med. 1975; 83: 281-282
        • Schwartz RS
        • Cohen JR
        • Schrier SL
        Therapy of primary amyloidosis with melphalan and prednisone.
        Arch Intern Med. 1979; 139: 1144-1147
        • Buxbaum JN
        • Hurley ME
        • Chuba J
        • Spiro T
        Amyloidosis of the AL type: clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone.
        Am J Med. 1979; 67: 867-878
        • Emmerich B
        • Kircher A
        • Fink U
        • Schmid L
        • Rostetter J
        Primare Amyloidose mit nephrotischem Syndrom: 5jähriger Verlauf unter kombinierter Chemotherapie.
        Klin Wochenschr. 1980; 58: 1207-1213
        • Kyle RA
        • Pierre RV
        • Bayrd ED
        Primary amyloidosis and acute leukemia associated with melphalan therapy.
        Blood. 1974; 44: 333-337
        • Kyle RA
        • Wagoner RD
        • Holley KE
        Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.
        Arch Intern Med. 1982; 142: 1445-1447
        • Mehta AD
        Regression of amyloidosis in multiple myeloma.
        Br J Clin Pract. 1978; 32: 358-359
        • Mehta AD
        Regression of amyloidosis in multiple myeloma.
        Br J Clin Pract. 1978; 32: 361
        • Bradstock K
        • Clancy R
        • Uther J
        • Basten A
        • Richards J
        The successful treatment of primary amyloidosis with intermittent chemotherapy.
        Aust NZ J Med. 1978; 8: 176-179
        • Corkery J
        • Bern MM
        • Tullis JL
        Resolution of amyloidosis and plasma-cell dyscrasia with combination chemotherapy (letter).
        Lancet. 1978; II: 425-426
        • Farhangi M
        • Thakur VM
        • Durham JB
        Objective response in amyloidosis treated with intermittent chemotherapy.
        South Med J. 1984; 77: 775-776
        • Kyle RA
        • Greipp PR
        Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo.
        Blood. 1978; 52: 818-827
        • Sohar E
        • Gafni J
        • Pras M
        • Heller H
        Familial Mediterranean fever: a survey of 470 cases and review of the literature.
        Am J Med. 1967; 43: 227-253
        • Goldfinger SE
        Colchicine for familial Mediterranean fever (letter).
        N Engl J Med. 1972; 287: 1302
        • Reimann HA
        Colchicine for periodic peritonitis.
        JAMA. 1975; 231: 64-66
        • Shirahama T
        • Cohen AS
        Blockage of amyloid induction by colchicine in an animal model.
        J Exp Med. 1974; 140: 1102-1107
        • Kedar (keizman) I
        • Ravid M
        • Sohar E
        • Gafni J
        Colchicine inhibition of casein-induced amyloidosis in mice.
        Isr J Med Sci. 1974; 10: 787-789
        • Zemer D
        • Pras M
        • Sohar E
        • Gafni J
        Colchicine in familial Mediterranean fever (letter).
        N Engl J Med. 1976; 294: 170-171
        • Nimoityn P
        • Lasker N
        • Soriano RZ
        Detection of urinary amyloid in familial Mediterranean fever.
        Br Med J. 1976; 2: 284
        • Melamed I
        • Shemer Y
        • Zakuth V
        • Tzehoval E
        • Pras M
        • Spirer Z
        The immune system in familial Mediterranean fever.
        Clin Exp Immunol. 1983; 53: 659-662
        • Selinger MJ
        • McAdam KPWJ
        • Kaplan MM
        • Sipe JD
        • Vogel SN
        • Rosenstreich DL
        Monokine-induced synthesis of serum amyloid A protein by hepatocytes.
        Nature. 1980; 285: 498-500
        • Tatsuta E
        • Sipe JD
        • Shirahama T
        • Skinner M
        • Cohen AS
        Colchicine inhibition of serum amyloid protein SAA and SAP synthesis in primary mouse liver cell cultures.
        Arthritis Rheum. 1984; 27: 349-352
        • Rubinow A
        • Cohen AS
        • Kayne H
        • Libbey CA
        Colchicine therapy in primary amyloidosis.
        in: A preliminary report. 2nd ed. Arthritis Rheum. 24. 1981: S124 (abstr)
        • Kyle RA
        Classification and diagnosis of monoclonal gammopathies, section B.
        in: 2nd ed. Manual of clinical immunology. American Society of Microbiology, Washington1980: 135-150
        • Michael J
        • Jones NF
        Spontaneous remissions of nephrotic syndrome in renal amyloidosis.
        Br Med J. 1978; 1: 1592-1593
        • Shirahama T
        • Cohen AS
        Redistribution of amyloid deposits.
        Am J Pathol. 1980; 99: 539-550